| Literature DB >> 24646632 |
Hasan Dogan1, Metin Akgun, Omer Araz, Elif Yilmazel Ucar, Ozgur Yoruk, Eda Diyarbakir, Omer Atis, Fatih Akdemir, Hamit Acemoglu, Ibrahim Pirim.
Abstract
BACKGROUND: Denim sandblasting may cause silicosis as a result of free crystalline silica inhalation. Its pathogenesis remains unclear, but autoimmunity may play a role in the development of silicosis. The present study aimed to investigate the relationships between human leukocyte antigen (HLA) and the severity and latency period of silicosis.Entities:
Year: 2014 PMID: 24646632 PMCID: PMC3994697 DOI: 10.1186/2049-6958-9-17
Source DB: PubMed Journal: Multidiscip Respir Med ISSN: 1828-695X
Demographic data, exposure characteristics, and lung function tests for the severe and mild groups
| Subjects (n) | 28 | 20 | - | - |
| Age (years) | 24.0 ± 9.5 | 23.4 ± 9.2 | - | NS* |
| BMI | 22.3 ± 2.7 | 22.5 ± 3.0 | - | NS* |
| Total exposure duration (months) | 35.7 ± 23.5 | 22.1 ± 21.1 | 0.004 | Significant |
| Latency period (months) | 58.1 ± 25.1 | 42.0 ± 30.6 | 0.044 | Significant |
| Smoking (pack/years) | 6.7 ± 2.3 | 5.9 ± 4.8 | - | NS* |
| FEV1 L | 3.2 ± 0.8 | 3.8 ± 0.5 | 0.003 | Significant |
| FEV1% pred | 80.0 ± 19.9 | 93.5 ± 21.1 | 0.003 | Significant |
| FVC L | 3.8 ± 0.9 | 4.6 ± 0.8 | 0.005 | Significant |
| FVC% pred | 81.6 ± 18.3 | 96.0 ± 24.9 | 0.004 | Significant |
| FEV1/FVC% | 80.0 ± 9.0 | 84.7 ± 7.5 | - | NS* |
*NS, Not significant; **Severe, the cases with 1/1 or higher ILO profusion. ***Mild, the cases with1/0 or lower ILO profusion without any symptoms, but with proof of the disease on HRCT.
Demographic data, exposure characteristics, and lung function tests according to latency period
| Subjects n | 23 | 25 | - | - |
| Age (years) | 22.4 ± 7.2 | 23.4 ± 8.5 | - | NS* |
| BMI | 21.7 ± 3.1 | 22.6 ± 2.6 | - | NS* |
| Total exposure duration (months) | 21.4 ± 13.9 | 38.0 ± 27.4 | 0.012 | Significant |
| Latency period (months) | 37.9 ± 17.6 | 73.0 ± 16.6 | 0.001 | Significant |
| Smoking (pack/years) | 3.9 ± 4.4 | 8.1 ± 6.5 | 0.014 | Significant |
| FEV1 L | 3.7 ± 0.6 | 3.3 ± 0.9 | - | NS* |
| FEV1% pred | 95.0 ± 18.7 | 83.4 ± 24.6 | - | NS* |
| FVC L | 4.4 ± 0.8 | 3.9 ± 1.0 | - | NS* |
| FVC% pred | 96.6 ± 19.3 | 83.5 ± 25.1 | 0.05 | Borderline |
| FEV1/FVC% | 84.3 ± 7.3 | 83.1 ± 9.4 | - | NS* |
*NS, Not significant; **Short latency, cases whose latency periods are ≤ 50 months. ***Long latency, cases whose latency periods are > 50 months.
Phenotype frequencies of HLA-ABDR alleles for severe and mild groups
| 5 (8.9%) | 4 (10.0%) | | NS* | |
| 16 (28.6%) | 6 (15.0%) | | NS* | |
| 5 (8.9%) | 2 (5.0%) | | NS* | |
| 10 (17.9%) | 6 (15.0%) | | NS* | |
| 0 (0.0%) | 3 (7.5%) | 0.069 | Borderline | |
| 12 (21.4%) | 11 (27.5%) | | NS* | |
| 3 (5.4%) | 1 (2.5%) | | NS* | |
| 1 (1.8%) | 2 (5.0%) | | NS* | |
| 2 (3.6%) | 3 (7.5%) | | NS* | |
| 1 (1.8%) | 1 (2.5%) | | NS* | |
| 0 (0.0%) | 1 (2.5%) | | NS* | |
| 1 (1.8%) | 0 (0.0%) | | NS* | |
| 5 (8.9%) | 3 (7.5%) | | NS* | |
| 2 (3.6%) | 1 (2.5%) | | NS* | |
| 2 (3.6%) | 1 (2.5%) | | NS* | |
| 3 (5.4%) | 0 (0.0%) | | NS* | |
| 1 (1.8%) | 0 (0.0%) | | NS* | |
| 17 (30.4%) | 13 (32.5) | | NS* | |
| 1 (1.8%) | 1 (2.5%) | | NS* | |
| 1 (1.8%) | 0 (0.0%) | | NS* | |
| 1 (1.8%) | 1 (2.5%) | | NS* | |
| 1(1.8%) | 3 (7.5%) | | NS* | |
| 1(1.8%) | 1 (2.5%) | | NS* | |
| 4 (7.1%) | 0 (0.0%) | | NS* | |
| 0 (0.0%) | 3 (7.5%) | 0.069 | Borderline | |
| 2 (3.6%) | 0 (0.0%) | | NS* | |
| 4 (7.1%) | 10 (25.0%) | 0.016 | Significant | |
| 3 (5.4%) | 0 (0.0%) | | NS* | |
| 1 (1.8%) | 0 (0.0%) | | NS* | |
| 5 (8.9%) | 0 (0.0%) | 0.062 | Borderline | |
| 2 (3.6%) | 2 (5.0%) | | NS* | |
| 0 (0.0%) | 1 (2.5%) | | NS* | |
| 4 (7.1%) | 2 (5.0%) | | NS* | |
| 10 (17.9%) | 2 (5.0%) | 0.055 | Borderline | |
| 5 (8.9%) | 3 (7.5%) | | NS* | |
| 2 (3.6%) | 2 (5.0%) | | NS* | |
| 12 (21.4%) | 11 (27.5%) | | NS* | |
| 4 (7.1%) | 7 (17.5%) | | NS* | |
| 5 (8.9%) | 6 (15.0%) | | NS* | |
| 9 (16.1%) | 5 (12.5%) | | NS* | |
| 5 (8.9%) | 2 (5.0%) | NS* |
*NS, Not significant; ** Percentages were calculated according to the allele number.
Phenotype frequencies of HLA-ABDR alleles according to latency period
| 5 (11.0%) | 4 (8.0%) | | NS* | |
| 11 (24.0%) | 11 (22.0%) | | NS* | |
| 4 (8.7%) | 3 (6.0%) | | NS* | |
| 8 (17.4%) | 8 (16.0%) | | NS* | |
| 1 (2.2%) | 2 (4.0%) | | NS* | |
| 8 (17.4%) | 15 (30.0%) | | NS* | |
| 2 (4.4%) | 2 (4.0%) | | NS* | |
| 2 (4.4%) | 1 (2.0%) | | NS* | |
| 4 (8.7%) | 1 (2.0%) | | NS* | |
| 0 (0.0%) | 2 (4.0%) | | NS* | |
| 1 (2.2%) | 0 (0.0%) | | NS* | |
| 0 (0.0%) | 1 (2.0%) | | NS* | |
| 3 (6.6%) | 5 (10.0%) | | NS* | |
| 1 (2.2%) | 2 (4.0%) | | NS* | |
| 3 (6.6%) | 0 (0.0%) | | NS* | |
| 2 (4.4%) | 1 (2.0%) | | NS* | |
| 1 (2.2%) | 0 (0.0%) | | NS* | |
| 15 (32.7%) | 15 (30.0%) | | NS* | |
| 1 (2.2%) | 1 (2.0%) | | NS* | |
| 1 (2.2%) | 0 (0.0%) | | NS* | |
| 1 (2.2%) | 1 (2.0%) | | NS* | |
| 1 (2.2%) | 3 (6.0%) | | NS* | |
| 2 (4.4%) | 0 (0.0%) | | NS* | |
| 2 (4.4%) | 2 (4.0%) | | NS* | |
| 2 (4.4%) | 1 (2.0%) | | NS* | |
| 1 (2.2%) | 1 (2.0%) | | NS* | |
| 8 (17.4%) | 6 (12.0%) | | NS* | |
| 0 (0.0%) | 3 (6.0%) | | NS* | |
| 0 (0.0%) | 1 (2.0%) | | NS* | |
| 2 (4.4%) | 3 (6.0%) | | NS* | |
| 2 (4.4%) | 2 (4.0%) | | NS* | |
| 0 (0.0%) | 1 (2.0%) | | NS* | |
| 1 (2.2%) | 5 (10.0%) | | NS* | |
| 4 (8.7%) | 8 (16.0%) | | NS* | |
| 6 (13.1%) | 2 (4.0%) | | NS* | |
| 2 (4.4%) | 2 (4.0%) | | NS* | |
| 12 (26.2%) | 11 (22.0%) | | NS* | |
| 6 (13.1%) | 5 (10.0%) | | NS* | |
| 6 (13.1%) | 5 (10.0%) | | NS* | |
| 5 (11%) | 9 (18.0%) | | NS* | |
| 2 (4.4%) | 5 (10.0%) | NS* |
*NS, Not significant; **Percentages were calculated according to the allele number.